The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication appears to provide significant improvements in fat reduction compared to current therapies. Preliminary clinical data have demonstrated significant decreases in weight , p